← Leaderboards
Zhiguo Zhou
Zymeron Corporation
$1,198,791
Attributed
$1,198,791
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $898.9K · FY2018–19$1M$750K$500K$250K$0
'18
'19
Funding mix
By agency
NIH$1,198,791 · 3
By mechanism
N01$898,871 · 2
N43$299,920 · 1
Top collaborators
No co-investigators on record.
Most similar at Zymeron Corporation
Same institution · by research overlap
- Michael Liu$1,722,693
- Yan Zhou$1,500,000
Others in their field
Other Emerging Leaders on “Screening”
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,487,925
- Lynn Briscoe · Leidos Biomedical Research, Inc.$121,890,535
- Yunda Huang · Fred Hutchinson Cancer Center$58,111,165
- Leonard Freedmand · Leidos Biomedical Research, Inc.$57,401,321
- John Damon Chodera · Sloan-Kettering Inst Can Research$53,758,943
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$33,980,897
Research focus
ScreeningPrototypeAffinityAntibioticsAntigensAspirinBiodistributionChemopreventionBloodCancer EtiologyCardiovascular Risk FactorCell LineCellsCessation Of LifeChemistryBedside TestingsChemopreventive AgentColonColorectal CancerColorectal Cancer PreventionControlled ReleaseCostDesignAged
Grant awards (3)
RAPID POINT OF CARE TESTS FOR TUBERCULOSIS$299,920
N43 · FY2019 · AI · contact PI
Synthetic Affinity Resins for One Step Purification of HIV Envelope Protein$599,061
N01 · FY2018 · AI · contact PI
Topic 374 - Phase I - Targeted and Sustained Release Microparticles for Colon CancerChemoprevention$299,810
N01 · FY2018 · CA · contact PI